Tokyo stands ready to offer an experimental drug
developed by a Japanese company to help stem the global tide of the deadly
Ebola virus, the top government spokesman said on Monday.

"Our
country is prepared to provide the yet-to-be approved drug in cooperation with
the manufacturer if the WHO requests," Chief Cabinet Secretary Yoshihide
Suga.
The World
Health Organization (WHO) has been discussing the use of unapproved drugs as a
way of getting a handle on an outbreak in Africa that has already cost more
than 1,400 lives, with thousands more people infected.
There is
currently no available cure or vaccine for Ebola, and the WHO has declared the
latest outbreak a global public health emergency.
Several
drugs are under development.
The
use of an experimental drug called ZMapp on two Americans and a Spanish priest
infected with the virus while working in Africa has opened up an intense
ethical debate.
The drug,
which is in very short supply, has reportedly shown promising results in the
two Americans, although the priest died.
US
company Mapp Bioparmaceutical which makes the drug said this month it had sent
all its available supplies to west Africa.
The WHO
earlier said a panel of medical experts had determined it is
"ethical" to provide experimental treatments.
Mr Suga
said on Monday: "Even before the WHO reaches a conclusion, we are ready to
respond to individual requests [from medical workers] under certain conditions
if it is an urgent case."
The
medication Mr Suga was referring to is Avigan, a drug in tablet form that was
approved as an anti-influenza drug in Japan in March and is currently in
clinical tests in the United States.
Its
developer Fujifilm Holdings said it had received inquiries from abroad but
declined to say how many and from which countries.
The company,
which has diversified into health care fields, has "no problem" over
the amount of stockpiles, according to spokesman Takao Aoki.
"We
have sufficient supplies for more than 20,000 people," he said.
Comments
Post a Comment